VEGFA and neoplasm: Another concern of neoadjuvant-targeted therapy has been the phenomenon of tumor “rebound.” While TKIs and VEGF-A decrease the vascularity of tumors, cessation of treatment can lead to rapid intratumoral angiogenesis and thus progression of disease.